A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Research and Clinical Trials Bookmark and Share

Research and Clinical Trials

City of Hope's Hematologic Malignancies and Stem Cell Transplantation Institute is recognized internationally for its breakthrough research discoveries and clinical trials for developing new ways to treat hematological cancers. Patients at City of Hope will have the ability to enroll in these trials, which can expand their treatment options and improve their outcomes. Learn more about our clinical trials program .
 
Highlights of our current research efforts include:

Reducing the Risk of GvHD
 
While stem cell transplants can be a lifesaving procedure for patients with hematologic disorders, it also carries a risk of graft versus host disease (GvHD), in which the newly transplanted stem cells do not recognize the recipient’s body as their own and start producing an immune response against it, leading to chronic and potentially serious complications. To reduce the likelihood of GvHD and to improve transplant outcomes, City of Hope is researching new ways to classify and match stem cell donors and recipients.
 
Adoptive T Cell Therapy
 
Harnessing the patient’s own immune system against the cancer, specifically through T-cell modification. In this experimental therapy, the patient’s own T-cells are extracted from the body, modified to recognize and attack cancer cells and re-infused back into the patient. This treatment has shown positive results for patients with lymphoma and lymphoid leukemia and is currently being studied for its potential against myeloid leukemia and multiple myeloma. Learn more about our Adoptive T Cell Therapy research.
 
Nonmyeloablative (Mini) Transplants
 
Our use and refinement of nonmyeloablative (“mini”) transplants, which relies less on the heavy doses of chemotherapy and radiation and more on the anti-cancer effects of the transplant itself. This novel approach allows otherwise ineligible patients, such as older patients or those who cannot tolerate radiation/chemotherapy-related effects, to be treated with this lifesaving procedure. Learn more about nonmyeloablative transplants.
 
Specialized Drug Studies
 
Continual development and improvement of drug regimens to treat hematologic cancers. Recently, City of Hope had led a national study of the drug brentuximab in patients with relapsed Hodgkin lymphoma, in whom the drug produced a high rate of response compared to standard therapy.
 
Leukemia Stem Cell Research
 
The Division of Stem Cell and Leukemia Research is currently investigating leukemia stem cells, which several studies have suggested to cause leukemia. By identifying and eradicating these cancerous stem cells — instead of just the mature leukemia cells that conventional therapies target — a definitive cure for this disease can be achieved.
 
Long-term Follow-up Program
 
City of Hope has a formal Long-term Follow-up Program that monitors all patients who have received a transplant at City of Hope to ensure they have optimal quality of life following their diagnoses and treatments. The program also helps researchers compile data on long-term outcomes to increase awareness of the kinds of problems, both physical and psychological, that some patients face after transplant, so patients can receive timely and appropriate information and care.
 
National Cancer Institute Project Grant
 
The City of Hope’s Hematologic Malignancies and Stem Cell Transplantation Institute has been continuously funded for nearly 30 years by the National Cancer Institute (NCI) to develop innovative therapies for people battling leukemia, lymphoma and other cancers. The NCI grant supports continuing research aimed at improving the outcome for patients undergoing either autologous or allogeneic transplant for a hematologic cancer. The grant also allows researchers at City of Hope to develop laboratory-based clinical studies to expand the scope and applications of stem cell transplants. These studies include incorporating gene transfer, molecular biology, radioimmunotherapy, cellular immunotherapy and genetics to improve transplant outcomes.
 
SPORE Grant
 
City of Hope was awarded a Specialized Program of Research Excellence (SPORE) grant to further its work in utilizing transplant and non-transplant approaches for the treatment of lymphoma. This SPORE is one of only five lymphoma SPORE awards granted in the United States and builds upon the expertise in the transplant and cancer immunotherapy programs at City of Hope.
 
 
If you have been diagnosed with a hematologic cancer or are looking for a second opinion consultation about your treatment, find out more about becoming a patient or contact us at 800-826-HOPE.
 

Research and Clinical Trials

Research and Clinical Trials

City of Hope's Hematologic Malignancies and Stem Cell Transplantation Institute is recognized internationally for its breakthrough research discoveries and clinical trials for developing new ways to treat hematological cancers. Patients at City of Hope will have the ability to enroll in these trials, which can expand their treatment options and improve their outcomes. Learn more about our clinical trials program .
 
Highlights of our current research efforts include:

Reducing the Risk of GvHD
 
While stem cell transplants can be a lifesaving procedure for patients with hematologic disorders, it also carries a risk of graft versus host disease (GvHD), in which the newly transplanted stem cells do not recognize the recipient’s body as their own and start producing an immune response against it, leading to chronic and potentially serious complications. To reduce the likelihood of GvHD and to improve transplant outcomes, City of Hope is researching new ways to classify and match stem cell donors and recipients.
 
Adoptive T Cell Therapy
 
Harnessing the patient’s own immune system against the cancer, specifically through T-cell modification. In this experimental therapy, the patient’s own T-cells are extracted from the body, modified to recognize and attack cancer cells and re-infused back into the patient. This treatment has shown positive results for patients with lymphoma and lymphoid leukemia and is currently being studied for its potential against myeloid leukemia and multiple myeloma. Learn more about our Adoptive T Cell Therapy research.
 
Nonmyeloablative (Mini) Transplants
 
Our use and refinement of nonmyeloablative (“mini”) transplants, which relies less on the heavy doses of chemotherapy and radiation and more on the anti-cancer effects of the transplant itself. This novel approach allows otherwise ineligible patients, such as older patients or those who cannot tolerate radiation/chemotherapy-related effects, to be treated with this lifesaving procedure. Learn more about nonmyeloablative transplants.
 
Specialized Drug Studies
 
Continual development and improvement of drug regimens to treat hematologic cancers. Recently, City of Hope had led a national study of the drug brentuximab in patients with relapsed Hodgkin lymphoma, in whom the drug produced a high rate of response compared to standard therapy.
 
Leukemia Stem Cell Research
 
The Division of Stem Cell and Leukemia Research is currently investigating leukemia stem cells, which several studies have suggested to cause leukemia. By identifying and eradicating these cancerous stem cells — instead of just the mature leukemia cells that conventional therapies target — a definitive cure for this disease can be achieved.
 
Long-term Follow-up Program
 
City of Hope has a formal Long-term Follow-up Program that monitors all patients who have received a transplant at City of Hope to ensure they have optimal quality of life following their diagnoses and treatments. The program also helps researchers compile data on long-term outcomes to increase awareness of the kinds of problems, both physical and psychological, that some patients face after transplant, so patients can receive timely and appropriate information and care.
 
National Cancer Institute Project Grant
 
The City of Hope’s Hematologic Malignancies and Stem Cell Transplantation Institute has been continuously funded for nearly 30 years by the National Cancer Institute (NCI) to develop innovative therapies for people battling leukemia, lymphoma and other cancers. The NCI grant supports continuing research aimed at improving the outcome for patients undergoing either autologous or allogeneic transplant for a hematologic cancer. The grant also allows researchers at City of Hope to develop laboratory-based clinical studies to expand the scope and applications of stem cell transplants. These studies include incorporating gene transfer, molecular biology, radioimmunotherapy, cellular immunotherapy and genetics to improve transplant outcomes.
 
SPORE Grant
 
City of Hope was awarded a Specialized Program of Research Excellence (SPORE) grant to further its work in utilizing transplant and non-transplant approaches for the treatment of lymphoma. This SPORE is one of only five lymphoma SPORE awards granted in the United States and builds upon the expertise in the transplant and cancer immunotherapy programs at City of Hope.
 
 
If you have been diagnosed with a hematologic cancer or are looking for a second opinion consultation about your treatment, find out more about becoming a patient or contact us at 800-826-HOPE.
 
Quick Links
About the HCT Program
Stephen J. Forman, M.D., chair of hematology and hematopoietic cell transplantation, shares his views on the essence of care at City of Hope. He highlights the bone marrow transplant program (BMT) and the program's growth over the years.
 
Other videos:
 
 
How to Become a Cure

 
What is a blood stem cell transplant? A remarkably effective treatment for leukemia, lymphoma, multiple myeloma - and many other diseases of the blood and bone marrow. This video shows the fascinating and dramatic journey of a blood stem cell donation all the way from a donor to a patient in need. Find out how you can become a bone marrow or stem cell donor »
Past BMT Reunions
Each year, City of Hope invites bone marrow transplant recipients and their families to attend the "Celebration of Life" event. View highlights from past reunions.
 
The focus of the Division of Hematopoietic Stem Cell and Leukemia Research is to improve the understanding of leukemia stem cells in order to develop cures for leukemia and other hematologic malignancies.
City of Hope's partnership with the Los Angeles Dodgers, includes ThinkCure!, an innovative, community-based non-profit that raises funds to accelerate collaborative research at City of Hope and Childrens Hospital Los Angeles to cure cancers.
 


NEWS & UPDATES
  • Patients with chronic lymphocytic leukemia may soon find themselves with improved treatment options. Interim results from a study not conducted at City of Hope suggest that, for patients with chronic lymphocytic leukemia, or CLL, a new oral drug given in combination with standard treatment significantly reduced...
  • The childhood journal of Kevin Chan, M.D., foreshadowed his future: At the tender age of 6, he wrote that he wanted to be a surgeon when he grew up. “I liked the idea of fixing broken arms and legs,” Chan said. “Back then, those were the procedures I could relate to.” Although his passion for […]
  • The outlook and length of survival has not changed much in the past 25 years for patients suffering from an aggressive form of pancreatic cancer known as pancreatic ductal adenocarcinoma (PDAC). These patients still have few options for therapy; currently available therapies are generally toxic and do not incre...
  • “With bladder cancer, the majority of patients that I see can be cured,” said urologist Kevin Chan, M.D., head of reconstructive urology at City of Hope. “The challenge is to get patients the same quality of life that they had before surgery.” To meet this challenge, Chan and the urologic team at City of Hope [...
  • Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine’s biggest challenges: brain cancer. This month, they will launch a clinical trial using patients’ own modified T cells to fight advanced brain tumors. One of but a...
  • Brain cancer may be one of the most-frightening diagnoses people can receive, striking at the very center of who we are as individuals. Further, it often develops over time, causing no symptoms until it’s already advanced. Listen to City of Hope Radio as Behnam Badie, M.D., director of the Brain Tumor Pro...
  • The whole is greater than the sum of its parts. It takes a village. No man is an island. Choose your aphorism: It’s a simple truth that collaboration usually is better than isolation. That’s especially true when you’re trying to introduce healthful habits and deliver health care to people at risk of disease and...
  • When Maryland Governor Larry Hogan announced earlier this week that he has the most common form of non-Hodgkin lymphoma, he was giving voice to the experience of more than 71,000 Americans each year. The announcement came with Hogan’s promise to stay in office while undergoing aggressive treatment for the...
  • The spine can be affected by many different kinds of tumors. Malignant, or cancerous, tumors can arise within the spine itself. Secondary spinal tumors, which are actually much more common, begin as cancers in another part of the body, such as the breast and prostate, and then spread, or metastasize, to the spi...
  • Although most cancer occurs in older adults, the bulk of cancer research doesn’t focus on this vulnerable and fast-growing population. City of Hope and its Cancer and Aging Research Team aim to change that, and they’re getting a significant boost from Professional Practice Leader Peggy Burhenn, R.N....
  • Liz Graef-Larcher’s first brain tumor was discovered by accident six years ago. The then-48-year-old with a long history of sinus problems and headaches had been sent for an MRI, and the scan found a lesion in her brain called a meningioma – a tumor that arises in the meninges, the layers of tissue that cover a...
  • The colon and rectum are parts of the body’s gastrointestinal system, also called the digestive tract. After food is digested in the stomach and nutrients are absorbed in the small intestine, the remaining material moves down into the lower large intestine (colon) where water and nutrients are absorbed. The low...
  • If there is one truism about hospital stays it is that patients want to get out. For many, however, the joy of being discharged is tempered by the unexpected challenges that recovery in a new setting may pose. Even with professional help, the quality of care and treatment that patients receive at City of Hope [...
  • Jana Portnow, M.D., associate director of the Brain Tumor Program at City of Hope, didn’t expect to specialize in treating brain tumors. But, early in her career, she undertook a year of research on pain management and palliative care and, in that program, got to know many patients with brain tumors. After that...
  • Ask any patient: Nurses are as pivotal in their care as doctors. They answer the call of a patient in the middle of the night, they hold the patient’s hand as he or she takes on yet another round of treatment and, in the best-case scenario, they wave goodbye as the patient leaves the hospital, […]